{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3
  ],
  "modelUsed": "gemini-3-flash-preview",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "5",
        "name": "Amendment 5",
        "scope": {
          "id": "07395f32-d5e9-4249-9639-8c360f7945c0",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "ad6a6125-60ce-4f16-93bd-cf355b9ae258",
          "code": {
            "id": "5d0d8e7c-e135-47aa-867c-e117a556a5a2",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "a60e5e45-82d9-415c-ab5b-a620dff9f443",
            "type": {
              "id": "414b57f8-0df8-4b08-b223-2af093d49c7d",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The Columbia Suicide Severity Rating Scale (C-SSRS) will be administered to all ongoing subjects at all remaining scheduled visits in Run In and Blinded treatments, and Rescue weeks 0, 8, 12, 16, and up to and including the End of Treatment/Early Termination (EOT/ET) and/or the End of Study (EOS) visit to align with new cross-program processes.",
        "effectiveDate": "2019-10-28",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2",
          "ar_1_3"
        ],
        "previousVersion": "4",
        "newVersion": "5"
      },
      {
        "id": "amend_2",
        "number": "4",
        "name": "Amendment 4",
        "scope": {
          "id": "24cb0366-9b65-4f11-bf22-ec0159b6603c",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "54e79c5f-2b35-4085-b19f-971d1fc7197b",
          "code": {
            "id": "20d900d5-6d2d-4b41-9674-53bfd494b24c",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "a7861fd1-0aef-4a26-af0a-7f710e2a7536",
            "type": {
              "id": "dd10705e-60de-411a-9f7d-050df3048345",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "For Taiwan only: Similar to China, other countries in Asia, such as Taiwan, have a high prevalence of hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, and hepatitis B surface antibody (HBsAb) positive serology. Therefore, Taiwan will adopt the same changes as those proposed for China in Amendment 3 to monitor the risk of hepatitis B reactivation.",
        "effectiveDate": "2018-11-27",
        "reasonIds": [
          "ar_2_1",
          "ar_2_2"
        ],
        "previousVersion": "3",
        "newVersion": "4"
      },
      {
        "id": "amend_3",
        "number": "3",
        "name": "Amendment 3",
        "scope": {
          "id": "223e24a1-3f0b-4d79-923d-12763d7d146f",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "1bbfce2a-7195-4bca-b554-d806edebe665",
          "code": {
            "id": "072f539f-2504-4eae-8cdf-b258e331087b",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "1462115d-5897-4f24-b6aa-33b08979027a",
            "type": {
              "id": "37550626-7932-447d-b988-a03899093fd4",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "The following changes, requested by an Ethics Committee in China for study B7451013, are being applied to the PF-04965842 program. These changes are in effect for China only: Subjects who are hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, and hepatitis B surface antibody (HBsAb) positive at Screening will have reflex testing for hepatitis B virus deoxyribonucleic acid (HBV DNA).",
        "effectiveDate": "2018-09-12",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "2",
        "newVersion": "3"
      },
      {
        "id": "amend_4",
        "number": "2",
        "name": "Amendment 2",
        "scope": {
          "id": "f4d294b0-64cd-4fd5-bba1-51787fdee7d4",
          "code": "Global",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Global",
          "instanceType": "Code"
        },
        "primaryReason": {
          "id": "4a82280f-2924-4d8e-b5b5-c194e0852a72",
          "code": {
            "id": "4d67f121-8f7c-43bb-8931-d66cb1e57db0",
            "code": "C98782",
            "codeSystem": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "codeSystemVersion": "25.01d",
            "decode": "Protocol Amendment",
            "instanceType": "Code"
          },
          "otherReason": "Protocol Amendment",
          "instanceType": "StudyAmendmentReason"
        },
        "geographicScopes": [
          {
            "id": "c654903b-fcd6-46aa-92b5-411e2b0726c8",
            "type": {
              "id": "2a2390f8-5d02-48f3-be1c-fa98505ee19d",
              "code": "Global",
              "codeSystem": "USDM",
              "codeSystemVersion": "2024-09-27",
              "decode": "Global",
              "instanceType": "Code"
            },
            "instanceType": "GeographicScope"
          }
        ],
        "instanceType": "StudyAmendment",
        "summary": "Updated Background and Rationale text to align across the JAK1 program; clarified primary and secondary objectives and endpoints; addition of Key Secondary endpoint; clarified study design and informed consent requirements; defined medicated topical therapy for clarity.",
        "effectiveDate": "2018-07-23",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3"
        ],
        "previousVersion": "1",
        "newVersion": "2"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_3",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_2",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "China",
        "instanceType": "Country",
        "code": "CN"
      },
      {
        "id": "country_2",
        "name": "Taiwan",
        "instanceType": "Country",
        "code": "TW"
      },
      {
        "id": "country_3",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 4,
      "countryCount": 3,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "Global",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1",
        "country_2",
        "country_3"
      ],
      "regions": [
        "Asia",
        "North America"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "5",
        "effectiveDate": "2019-10-28",
        "summary": "The Columbia Suicide Severity Rating Scale (C-SSRS) will be administered to all ongoing subjects at all remaining scheduled visits in Run In and Blinded treatments, and Rescue weeks 0, 8, 12, 16, and up to and including the End of Treatment/Early Termination (EOT/ET) and/or the End of Study (EOS) visit to align with new cross-program processes.",
        "previousVersion": "4",
        "newVersion": "5",
        "reasons": [
          "Operational",
          "Administrative",
          "Scientific"
        ]
      },
      {
        "number": "4",
        "effectiveDate": "2018-11-27",
        "summary": "For Taiwan only: Similar to China, other countries in Asia, such as Taiwan, have a high prevalence of hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, and hepatitis B surface antibody (HBsAb) positive serology. Therefore, Taiwan will adopt the same changes as those proposed for China in Amendment 3 to monitor the risk of hepatitis B reactivation.",
        "previousVersion": "3",
        "newVersion": "4",
        "reasons": [
          "Safety",
          "Regulatory"
        ]
      },
      {
        "number": "3",
        "effectiveDate": "2018-09-12",
        "summary": "The following changes, requested by an Ethics Committee in China for study B7451013, are being applied to the PF-04965842 program. These changes are in effect for China only: Subjects who are hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, and hepatitis B surface antibody (HBsAb) positive at Screening will have reflex testing for hepatitis B virus deoxyribonucleic acid (HBV DNA).",
        "previousVersion": "2",
        "newVersion": "3",
        "reasons": [
          "Regulatory",
          "Safety"
        ]
      },
      {
        "number": "2",
        "effectiveDate": "2018-07-23",
        "summary": "Updated Background and Rationale text to align across the JAK1 program; clarified primary and secondary objectives and endpoints; addition of Key Secondary endpoint; clarified study design and informed consent requirements; defined medicated topical therapy for clarity.",
        "previousVersion": "1",
        "newVersion": "2",
        "reasons": [
          "Scientific",
          "Administrative",
          "Operational"
        ]
      }
    ],
    "geographicScope": {
      "type": "Global",
      "countries": [
        {
          "name": "China",
          "code": "CN"
        },
        {
          "name": "Taiwan",
          "code": "TW"
        },
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "Asia",
        "North America"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}